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artery FMD represents a largely nitric oxide-mediated, endothelium-
dependent dilation and is attenuated by preceding forearm IR. FMD 
is a well-validated model to study IR-injury in humans. Forearm 
ischemia was induced by inflating a blood pressure cuff around the 
upper arm level. FMD analysis was performed offline by investigators 
blinded to the treatment arm.
Results: Baseline FMD did not differ between metformin pretreat-
ment and no pretreatment (6.9% [3.6%] and 6.1% [3.5%], respec-
tively; P = 0.27). FMD was significantly lower after forearm IR in 
both treatment arms (4.4% [3.3%] and 4.3% [2.8%], respectively; 
P < 0.01 in both groups). A 2-way repeated measures ANOVA 
revealed that metformine treatment did not prevent the decrease in 
FMD by IR (P = 0.50).
Conclusion: In this study, we investigated for the first time whether 
treatment with metformin limits IR-injury in humans in vivo. In con-
trast with previous studies in animal models of myocardial infarction, 
we did not observe any protective effect of metformin on endothelial 
IR-injury, measured with brachial artery FMD, in healthy middle-
aged volunteers. Our study does not exclude that metformin has pro-
tective effects in patients with cardiovascular disease or patients with 
DM. As such, additional studies, including studies in these patient 
groups, are needed to explore the discrepancy between the previous 
preclinical findings and our current results.
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Introduction: Ticagrelor is a P2Y12 receptor antagonist, with supe-
rior effects but also ensuing enhanced bleeding risk compared with 
clopidogrel. Determination of platelet inhibition may be useful to 
confirm efficient platelet inhibition on an individual patient level and 
to identify patients at risk for bleeding, particularly in a preopera-
tive setting. The vasodilator-associated stimulated phosphoprotein 
(VASP) phosphorylation assay specifically measures platelet P2Y12 
inhibition but has so far required special flow cytometric equipment 
and individual sample processing. A new ELISA-based VASP assay 
has been developed that allows batch analysis after initial platelet 
activation. Due to the reversible binding of ticagrelor, it is unclear if 
the ELISA and flow cytometric assays provide comparable results.
Patients (or Materials) and Methods: We hypothesized that the con-
ventional and new methods may be comparable when the revers-
ible P2Y12 inhibitor ticagrelor is used. We pair-wise compared the 
platelet reactivity index (PRI) between assays in a prospective clinical 
trial. Healthy volunteers received a single 180-mg loading dose of 
ticagrelor.
Results: PRI-values of the 2 methods correlated well (r = 0.97, P < 
0.001). Ticagrelor rapidly decreased PRI values on average after 50 
minutes, but nadir levels 2 to 6 hours after ticagrelor intake were 
15% higher when PRI% was measured with the flow cytometric 
method. Bland-Altman analysis showed that the flow cytometric 
assay measured markedly higher PRI levels than the new ELISA-
based technique (mean difference, 13%).
Conclusion: The new ELISA-based VASP assay offers an alternative 
to the currently used flow cytometric method, but measures lower 
PRI levels, particularly when PRI falls below 20% after ticagrelor 
intake.
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Introduction: Primary aldosteronism (PA) is the most prevalent form 
of endocrine hypertension, due to autonomous aldosterone produc-
tion. The 2 main causes of PA are aldosterone-producing adenome 
(APA) and bilateral adrenal hyperplasia (BAH). Aldosterone, syn-
thesized and secreted by the zona glomerulosa (ZG) of the adrenal 
gland, is physiologically regulated by angiotensin II (AngII), plasma 
potassium concentration [K+], and ACTH. However ,the molecu-
lar mechanisms that lead to the aldosterone hyperproduction are 
not completely understood. Recent studies have show the presence 
of somatic mutations of the inwardly rectifying potassium channel 
(KCNJ5) gene in APA, coding for the K+ channel KCNJ5. These 
mutations lie near or within the selectivity filter of the Kir3.4 channel, 
changing the normal Na+/K+ permability of the channel. Mutation-
scanning studies conducted on an Australian cohort with PA has 
identified germline single nucleotide polymorphisms (SNP) in the 
KCNJ5 gene (Q282E, E246K, and G247R) that may be relevant to 
the pathophysiology of PA in these subjects. However, the functional-
ity of these SNPs is unknown, so we have tested this directly.
Patients (or Materials) and Methods: The electrophysiology of these 
mutants was studied by applying a 2-electrode voltage clamp tech-
nique to Xenopus oocytes expressing the mutant KCNJ5 channels. A 
human H295R adrenocortical cell line was used as the experimental 
model to study the effects of the mutations on aldosterone release. 
Cells were transiently transfected with the WT KCNJ5 or mutant 
forms, and the aldosterone release was evaluated using a radioim-
munoassay, both under normal conditions and after depolarization 
with high extracellular K+ and Ang II.
Results: The Q282E and E246K KCNJ5 showed change in the selec-
tivity of the channel, with Na+ currents being observed in both of 
them. However, the G247R KCNJ5 behaved like the WT KCNJ5 
channel. Differences were also observed in the levels of aldosterone 
release from H295R cells expressing the different mutations, the 
details of which will be presented in the poster.
Conclusion: The findings from this work suggest that SNPs and 
rare variants outside the selectivity filter of KCNJ5 are functionally 
important and may be have a role in the autonomous aldosterone 
release in subjects with PA.
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Introduction: Hypoglycemic activity is one of the most important 
features of insulin derivatives and can be examined both in vitro and 
in vivo. The aim of the study was to evaluate activity of a new long-
acting insulin analogue using 3 different test systems.
Poster Presentation Abstracts
2013 e43
Patients (or Materials) and Methods: New insulin analogue AKR 
of a potential long-acting feature was evaluated in the Institute of 
Biotechnology and Antibiotics. Bioactivity of AKR was compared 
with that of USP human insulin standard in bioassays on cells and 
rabbits, while the pharmacodynamic activity on rats was referred to 
control group received 0.9% NaCl. The 3T3-L1 cells differentiated 
into adipocytes were used for the performance of insulin dependent 
glucose uptake experiment. Dose-response relationship of log insu-
lin concentration and Deoxy-D-glucose uptake of AKR was deter-
mined. The biological activity on animals was assessed on 24 albino 
rabbits according to US Pharmacopeia. The glucose concentrations 
were measured with spectrophotometer in 2 time points (1.0 and 
2.5 hours) after administration of 1 U and 2 U of insulin. Potency 
of AKR was calculated with 95% CI. Pharmacodynamic effect was 
based on glucose concentration measurement in rats with hypergly-
cemia induced by streptozotocin. The overall glycemic profile up to 
36 hours was evaluated after subcutaneous single dosing at range 
2.5 to 10.0 U/kg b.w. In the 28-day multiple dose study, AKR was 
administered twice a day at dose 5.0 U/kg b.w.
Results: Percentage of maximum Deoxy-D-glucose uptake in 3T3-
L1 cells was similar for AKR and human insulin, except the highest 
concentration in which the hook effect was observed. The absolute 
potency of a new analogue determined in rabbits was 23.94 U/mg, 
and the potency ratio of AKR versus the insulin standard was 0.90. 
The relative potency was 38.35 U/mL with confidence limit of 32.99–
44.42 U/mL. The experiment on rats confirmed with a statistical 
significance (P < 0.05) hypoglycemic activity of AKR in comparison 
of control group both after single and multiple doses. Characteristics 
for AKR profile was rather fast beginning of action (0.5-1.0 hour) 
with the maximal effect at 6 hours postdose and quite prolonged 
return to initial values. The glucose levels were stable during 4-week 
administration.
Conclusion: Bioactivity of the novel insulin analogue AKR, con-
nected with glucose metabolism was confirmed in both in vitro and in 
vivo conditions. AKR is a candidate for a hypoglycemic drug product 
in diabetes care.
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Introduction: Current acute myocardial infarction (AMI) guidelines 
recommend the use of platelet aggregation inhibitors, beta-blockers, 
angiotensin-converting enzyme inhibitors (ACEI), or angiotensin II 
receptor blockers (ARB) and statins for in-hospital and long-term 
treatment. The aim of the study was to evaluate the changes in the 
prescription of these drugs in Estonian hospitals in 2001 versus 2007 
and in 2007 versus 2011.
Patients (or Materials) and Methods: We performed a retrospective 
cross-sectional study including random samples of hospitalized AMI 
cases. Chi-square test and logistic regression were used to study the 
changes in the prescription of the drugs.
Results: Final analysis included 423 cases in 2001, 687 cases in 2007, 
and 740 cases in 2011. The prescription rates of most drugs recom-
mended for in-hospital and for out-patient use improved (Table). 
Compared with 2001, in 2007 and 2011, more patients were pre-
scribed drugs from all 5 drug (sub)groups during hospitalization 
(3.3% vs 18.5% vs 26.5%; P < 0.001) and for outpatient use (3.8% 
vs 22.2% vs 33.1%; P < 0.001). In multivariate analysis, < 75-year-
old patients and those hospitalized into a tertiary care hospital were 
more likely to be prescribed drugs from all 5 drug (sub)groups.
Conclusion: Prescription of recommended drugs for AMI patients 
increased continuously during last years in Estonia. Continuous edu-
cation programs and future studies should focus to differences of 
drug utilization in tertiary and nontertiary hospitals, also to different 
patient subgroups (ie, elderly).
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Introduction: There are potential conflicts between authorities and 
companies to fund new premium-priced drugs, especially where 
there are safety and/ or budget concerns. Dabigatran exemplifies 
these issues due to variable drug concentrations, no known antidote, 
dependence on renal elimination, and considerably more expensive 
than warfarin. The latter is a concern with the growing prevalence 
of atrial fibrillation (AF). There are also issues with potentially 
re-designing anticoagulant services. As a result, there is a need to 
review authority activities regarding dabigatran and use the findings 
to develop new models to better manage the entry of new drugs in 
the future.
Patients (or Materials) and Methods: Descriptive review and 
appraisal of educational and other activities regarding dabigatran 
pre- to postlaunch in a systematic manner among > 30 European 
countries and regions. The findings were used to develop a new model 
Table. Prescription rates of recommended drugs in Estonia.
Year 2001 Year 2007
P 2001 vs 
2007 Year 2011
P 2007 vs 
2011
During hospitalization n = 423 n = 687 n = 740
Aspirin 87.7 90.1 0.212 88.5 0.333
P2Y12 inhibitors 8.5 34.8 < 0.001 42.3 0.004
Beta-blockers 77.8 80.1 0.363 76.2 0.080
ACEI/ARB 53.7 68.3 < 0.001 63.5 0.059
Statins 16.1 48.5 < 0.001 58.0 < 0.001
Outpatient use n = 344 n = 514 n = 473
Aspirin 82.6 88.5 0.013 92.0 0.069
P2Y12 inhibitors 9.9 41.1 < 0.001 52.9 < 0.001
Beta-blockers 70.1 80.4 0.001 82.9 0.307
ACEI/ARB 52.6 73.7 < 0.001 75.9 0.434
Statins 23.5 57.6 < 0.001 72.3 < 0.001
